Tetra Bio-Pharma Files New Drug Submission for REDUVO(TM) in Canada
The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of
Read more
tetrabiopharma
Tetra Bio Pharma Announces Divestiture of Lumiera Health Innovation Inc.
OTTAWA, ON / ACCESSWIRE / October 28, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug
Read more
IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Technology for Dronabinol
SAINT LAURENT, Quebec, Oct. 21, 2020 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has
Read more
Tetra Bio-Pharma Announces Positive Results in Animal Studies for Treatment of Hyperinflammatory Lung Injury
Reduced the levels of key inflammatory cytokine markers Reduced fibrosis when the lung tissue was analyzed Reduced the effects of
Read more
Tetra Bio-Pharma (TBP) Acquires Dronabinol Soft Gel Capsules Exclusive Canadian Distribution Rights to Establish a Strong Commercial Presence in Canada and Accelerate its Profitability
Tetra is ready to submit its first New Drug Submission application to commercialize a THC-based prescription drug in Canada. Will
Read more
Tetra Bio-Pharma Appoints Chief Financial Officer
OTTAWA, ON / ACCESSWIRE / September 11, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived
Read more
Dania Scott Joins Tetra Bio-Pharma as Senior Vice President Commercial Strategy
Brings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis space OTTAWA, ON /
Read more
Tetra Bio-Pharma Announces Plenitude Clinical Trial is Initiated
Pharmaceutical GMP grade QIXLEEF™ shipped OTTAWA, ON / ACCESSWIRE / September 2, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF),
Read more
Tetra Bio-Pharma Announces Expected Effective Date of Listing on TSX of its Common Shares and Warrants
Canada NewsWire OTTAWA, ON, July 30, 2020 /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ OTTAWA, ON, July
Read moreTetra Bio-Pharma Discusses the Potential of Their ARDS-003 Drug in the Fight Against COVID-19 with the Stock Day Podcast (TBPMF) June 22, 2020
Newsfile Corp.Newsfile Corp Phoenix, Arizona–(Newsfile Corp. – June 22, 2020) – The Stock Day Podcast welcomed Tetra Bio-Pharma (TSXV: TBP) (OTCQB:
Read more
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
OTTAWA, ON / ACCESSWIRE / June 3, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSXV:TBP)(OTCQB:TBPMF) and Altus Formulation Inc.
Read more
Tetra Bio-Pharma Provides HCC011 Program Update Following Type B Meeting with USA FDA
HCC011 is an orphan drug designated drug-device combination product for the treatment of hepatocellular carcinoma (HCC) OTTAWA, ON / ACCESSWIRE
Read more